A peptide platform, headquartered in Dubai

Building the safety,
manufacturing, and
clinical infrastructure
the global peptide
market is missing.

A Dubai-headquartered platform company. Manufacturing, testing, clinical and patient-facing software, designed as one stack rather than four catalogues.

HeadquartersDubai, United Arab Emirates

HeritageGenesis Peptides, United States

StagePre-MOU, capital formation

Doc revisionv 0.1, 2026-05-14, 14:30 GST

PL · 01 editorial still, vials on bench

§ 01 Opportunity

Peptide therapeutics are the fastest-moving modality in metabolic and longevity medicine. The Gulf market is underserved by the supply chain that exists. The Gulf is also positioned to host the supply chain that should.

USD 1.2B¹ GCC addressable, 2030 Peptide therapeutics plus metabolic and longevity adjacencies across the six GCC member states, base case.

14%² Compound annual growth Five-year CAGR, 2025 through 2030, driven by metabolic prescribing and out-of-pocket longevity demand.

0³ Regional manufacturers, end-to-end No GCC-domiciled producer currently runs API synthesis, fill-finish, and the full safety panel under one roof.

Sources · ¹ UAE Peptide Market Analysis v5, §3.2 · ² Ibid, §4.1 · ³ Competitive landscape audit, 2026-Q1

§ 02 · The arc

We had a company in the United States. The regulatory market there is not conducive to what we know is possible. We are moving headquarters to Dubai, forming a new entity, and building a platform. Peptides first, because that is where we have depth. Then clinical infrastructure, education, and the patient app.

Origin in the United States.

Genesis Peptides operated as a research-supply business and accumulated five years of formulation, sourcing, and analytical depth. The catalogue model capped what the company could become.

Disassociation, then relocation.

Helix Dubai is incorporated as a separate entity. The US operation does not move with it. The platform thesis, the team, and the manufacturing roadmap do.

Platform, not catalogue.

Four pillars in one company. Commercial manufacturing. Clinical and education. Patient software. Testing and safety. Each one is a defensible business; together they are a moat.

Then the world.

Dubai is the headquarters and the proving ground. The protocols, the supply chain, and the regulatory dossiers are built to export.

§ 03 Platform

Four pillars, one company. Each pillar is engineered to stand on its own balance sheet. Together they form an integrated production, distribution, and clinical stack.

PILLAR 01Commercial

Commercial & Manufacturing.

Phased build, from imported and tested API in year one to local fill-finish in year two to full API synthesis in year three. Cold-chain logistics, batch traceability with QR plus blockchain anchoring, and a regulatory dossier engineered for GCC plus international markets.

Read the roadmap

PILLAR 02Clinical

Clinical & Education.

Provider training, prescriber networks, and protocol development for the metabolic, performance, and longevity indications that drive volume in this region. A clinical advisory board sits between manufacturing and the patient-facing tier.

See the pipeline

PILLAR 03Patient

Patient App.

A mobile application that pairs each prescription with adherence guidance, biomarker tracking, and a verified-supply check. Closes the loop between manufacturing batch identity and the patient who receives it.

Product pipeline

PILLAR 04Safety

Testing & Safety.

A five-test analytical panel run on every commercial lot. Identity, purity, endotoxin, sterility, and residual solvent. Most competitors run two or three. The differential is the platform.

View the matrix

§ 04 Manufacturing

Three phases, four years. Each phase is independently financeable. Each phase produces revenue. The roadmap is sequential by design, so capital is matched to capability rather than to ambition.

2026 Q32027202820292030 Q1

Phase I · 2026–2027

Import, test, distribute.

Sourced APIs from qualified Chinese and Indian producers.
In-house identity, purity, and endotoxin testing on arrival.
Fill-finish performed under contract with a Dubai partner facility.
Distribution to GCC clinics through licensed prescribers.

Phase II · 2028

Local semi-manufacturing.

Owned fill-finish line and analytical laboratory inside a Dubai free-zone facility.
Full five-test panel run on every commercial lot, in-house.
Batch traceability stack live, QR plus blockchain anchor.
First export dossier filed for adjacent GCC markets.

Phase III · 2029–2030

Full API synthesis.

Solid-phase peptide synthesis line, GCC-first scale.
Forward-integrated raw-material qualification and recycling.
Regulatory dossier readied for additional international markets.
Platform unit economics independent of upstream API price.

A roadmap reads left to right. Each block above is a year-range of activity. Imported API and contract fill-finish front-load revenue while owned capacity is built. By the third block, the platform makes the active ingredient itself, with the testing and traceability already in place.

§ 05 Testing & Safety

A peptide that has not been tested for endotoxin is a peptide whose patient outcome is a matter of luck. Helix Dubai runs the full panel as a precondition for lot release.

Analytical test

Helix Dubai

Tier-1 pharma peer

Research-supply seller

Grey-market vial

Identity by mass spectrometryConfirms the molecule in the vial is the molecule on the label.

✓

Purity by HPLCQuantifies the active material as a percent of total mass.

✓

Endotoxin by LALDetects bacterial fragments that trigger systemic inflammation.

✓

Sterility by membrane filtrationConfirms no viable bacterial or fungal contamination at fill.

✓

Residual solvent by GCMeasures trace synthesis solvents left over in the finished material.

✓

✓ Run on every lot ~ Run on some lots, or to a lower standard · Not run

A test matrix reads down the rows. Each row is one analytical test. The first column lists what the test answers in plain terms. Every column to the right reports whether that supplier runs the test on every shipped lot.

§ 06 Pipeline

Three portfolio scenarios. The base case is what Helix Dubai commits to. The conservative case is what survives any phasing slip. The expanded case is what becomes possible once Phase II capacity is live.

Product category

Conservative

Base case

Expanded

Phase available

Metabolic regulation

3 SKU

5 SKU

7 SKU

Phase I

Tissue repair

2 SKU

3 SKU

5 SKU

Phase I

Cognitive support

1 SKU

2 SKU

3 SKU

Phase II

Hormonal modulation

1 SKU

2 SKU

3 SKU

Phase II

Longevity adjuncts

1 SKU

3 SKU

Phase III

A pipeline grid reads across the rows. Each row is a product category. Each column shows how many distinct products that category contains under three financing scenarios. Bar length shows scenario coverage relative to the expanded case. Specific molecule names are withheld at this stage.

§ 07 Market

Two structural facts shape the regional opportunity. Demand is inelastic and growing. Supply is fragmented, undertested, and almost entirely imported.

Demand is structural. Metabolic disease prevalence in the GCC sits among the highest in the world. Out-of-pocket spending on longevity and performance medicine is a multiple of the global average. Both lines grow regardless of macro conditions, because both lines map to chronic health status rather than discretionary consumption.

Supply is imported and uneven. Substantially all peptide therapeutics dispensed in the region today are sourced through cross-border channels from suppliers that run a subset of the standard analytical panel. The downstream provider has no practical way to verify identity, purity, or endotoxin at the point of dispense.

The arbitrage is the platform. A regional producer that ships fully tested product, with a verifiable batch trail and a prescriber-facing protocol library, displaces the imported supply chain on quality, on lead time, and on regulatory standing.

Regional peptide market, indicative.

GCC addressable, USD billions, 2024 to 2030

0.6

'24

0.7

'25

0.8

'26

0.9

'27

1.0

'28

1.1

'29

1.2

'30

A bar chart reads left to right. Taller bars are larger figures. Each bar is one calendar year, in USD billions of addressable revenue. Source, UAE Peptide Market Analysis v5, §4.

§ 08 Team

Small operating team, deep advisory bench. Helix Dubai is being built with the people who built Genesis in the United States, augmented by Gulf-resident scientific and regulatory advisors.

jay spall, editorial portrait

Jay Spall

Founder, CEO

Built and operated Genesis Peptides in the United States. Now leading the formation of the Dubai platform and the supply-chain rebuild around it.

steve mescon, editorial portrait

Steve Mescon

Co-founder, Commercial

Operating partner across capital formation, partnerships, and go-to-market. Long-standing collaborator on the Genesis platform thesis.

scientific advisor, editorial portrait

Scientific Advisory

Manufacturing & analytical

Two senior advisors. Peptide synthesis, GMP fill-finish, and analytical method development. Names available under signed NDA.

§ 09 Investment

Capital formation is in progress. Detail, including round structure, valuation, and use of proceeds, is shared under standard process after MOU is in motion.

Detail is provided on request to vetted investors after MOU is in motion.

Helix Dubai is currently in MOU review with a Dubai government counterparty. Investment materials, including round structure, instrument, valuation, and use of proceeds, are shared after introduction and on a vetted basis. The public site does not list a target figure by design.

Response within 2 business days, 09:00 to 18:00 GST.

§ 10 · The ask

One platform, one company, one location. The capital builds the manufacturing capability and the testing capability, in that order.

Request investor materials

Capital useManufacturing, then testing capacity

TimelinePhase I revenue inside 12 months of close

VehicleUAE-domiciled new entity, separate from Genesis United States

ProcessMOU review, then introductions to vetted investors

Contactteam@helix-dubai.example

Private preview.

Building the safety,
manufacturing, and
clinical infrastructure
the global peptide
market is missing.

Origin in the United States.

Disassociation, then relocation.

Platform, not catalogue.

Then the world.

Commercial & Manufacturing.

Clinical & Education.

Patient App.

Testing & Safety.

Import, test, distribute.

Local semi-manufacturing.

Full API synthesis.

Regional peptide market, indicative.

Jay Spall

Steve Mescon

Scientific Advisory

Detail is provided on request to vetted investors after MOU is in motion.

One platform, one company, one location. The capital builds the manufacturing capability and the testing capability, in that order.

Tweaks close